Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults

Human Vaccines

Volumn 5, Issue 8, 2009, Pages 536-544

  Keitel, Wendy A ^b   Treanor, John J ^c   El Sahly, Hana M ^b   Evans, Thomas G ^d   Kopper, Scott ^e   Whitlow, Vanessa ^f   Selinsky, Cheryl ^g   Kaslow, David C ^h   Rolland, Alain ^a   Smith, Larry R ^a   Lalor, Peggy A ⁱ  

^a VICAL INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d NOVARTIS   (United States)

^e IQVIA   (United States)

^f Synteract Inc   (United States)

^g TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ Histion LLC   (United States)

Author keywords

Anthrax; B. anthracis; Challenge; Clinical; Nonhuman primate; Safety; Survival; Vaccine

Indexed keywords

ANTHRAX VACCINE; PLACEBO; PLASMID DNA; UNCLASSIFIED DRUG; VCL AB01;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTIGENICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY MASS; LETHAL GENE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MYALGIA; NONHUMAN; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIMATE; RABBIT; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEROCONVERSION; SPLEEN WEIGHT; SYSTEMIC DISEASE; SYSTOLIC HYPERTENSION;

ADOLESCENT; ADULT; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS; MALE; MIDDLE AGED; NEW YORK; RABBITS; TEXAS; VACCINATION; VACCINES, DNA;

EID: 68349143391     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.8.8725     Document Type: Article

References (19)

1. Mock M, Fouet A. Anthrax. Annu Rev Microbiol 2001; 55:647-71.
2. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236-52.
3. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202-8.
4. Brookmeyer R, Blades N. Prevention of inhalational anthrax in the U.S. outbreak. Science 2002; 295:1861.
5. Bhatnagar R, Batra S. Anthrax toxin. Crit Rev Microbiol 2001; 27:167-200.
6. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007; 3:205-11.
7. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006; 24:5950-9.
8. Ferrari ME, Hermanson G, Rolland A. Development of anthrax DNA vaccines. Curr Opin Mol Ther 2004; 6:506-12.
9. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19:3241-7.
10. Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 1999; 17:340-4.
11. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004; 101:13601-6.
12. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65:5171-5.
13. McBride BW, Mogg A, Telfer JL, Lever MS, Miller J, Turnbull PC, et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16:810-7.
14. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19:4768-73.
15. Vilalta A, Mahajan RK, Hartikka J, Leamy V, Martin T, Rusalov D, et al. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum Gene Ther 2005; 16:1151-6.
16. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006; 24:3654-60.
17. Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004; 190:1228-36.
18. Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, et al. Specific, sensitive and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002; 8:1103-10.
19. Selinsky CL, Whitlow VD, Smith LR, Kaslow DC, Horton HM. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen. Biologicals 2007; 35:123-9.